Symbols / ASND Stock $229.64 -0.61% Ascendis Pharma A/S
ASND (Stock) Chart
About
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Stock Fundamentals
Scroll to Statements| Market Cap | 14.19B | Enterprise Value | 14.44B | Income | -228.03M | Sales | 720.13M | Book/sh | -3.12 | Cash/sh | 10.04 |
| Dividend Yield | — | Payout | 0.00% | Employees | 1189 | IPO | — | P/E | — | Forward P/E | 25.41 |
| PEG | — | P/S | 19.70 | P/B | -73.71 | P/C | — | EV/EBITDA | -109.86 | EV/Sales | 20.05 |
| Quick Ratio | 0.72 | Current Ratio | 1.04 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -4.44 | EPS next Y | 9.04 |
| EPS Growth | — | Revenue Growth | 42.30% | Earnings | 2026-04-30 | ROA | -6.86% | ROE | — | ROIC | — |
| Gross Margin | 86.82% | Oper. Margin | 0.96% | Profit Margin | -31.67% | Shs Outstand | 61.78M | Shs Float | 60.92M | Short Float | — |
| Short Ratio | — | Short Interest | — | 52W High | 250.74 | 52W Low | 150.89 | Beta | 0.48 | Avg Volume | 661.11K |
| Volume | 114.15K | Target Price | $339.76 | Recom | Buy | Prev Close | $231.05 | Price | $229.64 | Change | -0.61% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-16 | main | B of A Securities | Buy → Buy | $292 |
| 2026-04-09 | reit | Wedbush | Outperform → Outperform | $273 |
| 2026-03-03 | main | RBC Capital | Outperform → Outperform | $275 |
| 2026-02-12 | main | Oppenheimer | Outperform → Outperform | $262 |
| 2026-02-12 | main | Wedbush | Outperform → Outperform | $273 |
| 2026-01-30 | main | B of A Securities | Buy → Buy | $260 |
| 2026-01-28 | init | Barclays | — → Overweight | $342 |
| 2026-01-20 | main | RBC Capital | Outperform → Outperform | $250 |
| 2026-01-20 | main | Wells Fargo | Overweight → Overweight | $330 |
| 2026-01-09 | main | Wells Fargo | Overweight → Overweight | $322 |
| 2026-01-07 | reit | TD Cowen | Buy → Buy | $325 |
| 2025-12-11 | main | Stifel | Buy → Buy | $256 |
| 2025-11-18 | reit | Wedbush | Outperform → Outperform | $220 |
| 2025-10-17 | init | Raymond James | — → Strong Buy | $271 |
| 2025-10-13 | main | Cantor Fitzgerald | Overweight → Overweight | $254 |
| 2025-10-09 | main | JP Morgan | Overweight → Overweight | $264 |
| 2025-09-02 | main | B of A Securities | Buy → Buy | $230 |
| 2025-08-19 | main | JP Morgan | Overweight → Overweight | $260 |
| 2025-08-08 | main | Citigroup | Buy → Buy | $290 |
| 2025-08-08 | main | RBC Capital | Outperform → Outperform | $230 |
- symbol__ Stock Quote Price and Forecast - CNN ue, 21 Apr 2026 22
- Best Buy's Sales and Stock Are Sluggish. Can a New CEO Bring Back Growth? - Investopedia Wed, 22 Apr 2026 18
- Ascendis swaps Nasdaq ADSs for ordinary shares under same ASND ticker - Stock Titan Mon, 20 Apr 2026 12
- Ascendis (ASND) Stock Analysis: Undervalued or Overpriced | Q4 2025: Earnings Underperform - Cyclicality - Cổng thông tin điện tử tỉnh Lào Cai hu, 23 Apr 2026 05
- Should You Forget Pfizer and Buy This Pharma Stock Instead? - The Motley Fool Wed, 22 Apr 2026 16
- Oil Prices Jump and Stocks Waver on Renewed Iran Conflict - The New York Times Sun, 19 Apr 2026 22
- Stock Market Today: Stock Market News And Analysis - Investor's Business Daily Wed, 22 Apr 2026 18
- Real-Time Prices, Charts & News | Deutsche Börse: Xetra & Frankfurt - Deutsche Börse Frankfurt Mon, 20 Apr 2026 07
- Ascendis Pharma (ASND) to List Ordinary Shares Directly on Nasdaq - Yahoo Finance Sun, 12 Apr 2026 07
- Ascendis moves to retire $575M in notes after stock clears trigger - Stock Titan ue, 21 Apr 2026 20
- Stock market today: Oil rises and stock futures drop as Trump makes apocalyptic threats against Iran - Fortune Sun, 05 Apr 2026 07
- Congressional Stock Trading and the STOCK Act - Campaign Legal Center Fri, 05 Sep 2025 07
- RSI Insider Sells $1.1 Million as Revenue Hits $1.1 Billion and Stock Doubles - The Motley Fool Wed, 22 Apr 2026 15
- symbol__ Stock Quote Price and Forecast - CNN Wed, 22 Apr 2026 12
- Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily Wed, 22 Apr 2026 17
Insider Transactions
No recent insider transactions.
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
720.13
+98.03%
|
363.64
+36.34%
|
266.72
+421.20%
|
51.17
|
| Operating Revenue |
|
720.13
+98.03%
|
363.64
+36.34%
|
266.72
+421.20%
|
51.17
|
| Cost Of Revenue |
|
94.92
+114.46%
|
44.26
-0.31%
|
44.40
+265.78%
|
12.14
|
| Reconciled Cost Of Revenue |
|
87.04
+159.01%
|
33.61
-24.30%
|
44.40
+265.78%
|
12.14
|
| Gross Profit |
|
625.22
+95.76%
|
319.38
+43.66%
|
222.32
+469.52%
|
39.04
|
| Operating Expense |
|
761.49
+27.31%
|
598.15
-11.76%
|
677.86
+12.82%
|
600.85
|
| Research And Development |
|
303.62
-1.10%
|
307.00
-25.75%
|
413.45
+8.91%
|
379.62
|
| Selling General And Administration |
|
448.04
+57.72%
|
284.08
+7.44%
|
264.41
+22.50%
|
215.85
|
| General And Administrative Expense |
|
448.04
+57.72%
|
284.08
+9.77%
|
258.79
+19.89%
|
215.85
|
| Salaries And Wages |
|
210.42
+45.94%
|
144.18
+24.61%
|
115.71
+23.12%
|
93.98
|
| Other Gand A |
|
237.63
+69.86%
|
139.90
-2.22%
|
143.08
+17.41%
|
121.87
|
| Total Expenses |
|
856.40
+33.31%
|
642.40
-11.06%
|
722.26
+17.83%
|
612.99
|
| Operating Income |
|
-136.27
+51.12%
|
-278.76
+38.81%
|
-455.54
+18.92%
|
-561.81
|
| Total Operating Income As Reported |
|
-136.27
+51.12%
|
-278.76
+38.81%
|
-455.54
+18.92%
|
-561.81
|
| EBITDA |
|
-114.31
+60.59%
|
-290.02
+29.46%
|
-411.17
+22.30%
|
-529.18
|
| Normalized EBITDA |
|
-66.50
+73.97%
|
-255.50
+39.67%
|
-423.51
+23.57%
|
-554.13
|
| Reconciled Depreciation |
|
17.70
-0.10%
|
17.71
-6.33%
|
18.91
+5.31%
|
17.96
|
| EBIT |
|
-132.00
+57.10%
|
-307.74
+28.45%
|
-430.08
+21.39%
|
-547.13
|
| Total Unusual Items |
|
-47.81
-38.49%
|
-34.52
-379.63%
|
12.35
-50.52%
|
24.95
|
| Total Unusual Items Excluding Goodwill |
|
-47.81
-38.49%
|
-34.52
-379.63%
|
12.35
-50.52%
|
24.95
|
| Net Income |
|
-228.03
+39.69%
|
-378.08
+21.47%
|
-481.45
+17.45%
|
-583.19
|
| Pretax Income |
|
-212.65
+43.03%
|
-373.24
+21.28%
|
-474.14
+17.94%
|
-577.82
|
| Net Non Operating Interest Income Expense |
|
-44.88
-12.49%
|
-39.90
-217.79%
|
-12.55
+46.02%
|
-23.26
|
| Interest Expense Non Operating |
|
80.65
+23.12%
|
65.50
+48.65%
|
44.06
+43.62%
|
30.68
|
| Net Interest Income |
|
-44.88
-12.49%
|
-39.90
-217.79%
|
-12.55
+46.02%
|
-23.26
|
| Interest Expense |
|
80.65
+23.12%
|
65.50
+48.65%
|
44.06
+43.62%
|
30.68
|
| Interest Income Non Operating |
|
15.30
+6.55%
|
14.36
-14.81%
|
16.86
+127.00%
|
7.43
|
| Interest Income |
|
15.30
+6.55%
|
14.36
-14.81%
|
16.86
+127.00%
|
7.43
|
| Other Income Expense |
|
-31.50
+42.28%
|
-54.58
-802.35%
|
-6.05
-183.40%
|
7.25
|
| Gain On Sale Of Security |
|
-47.81
-38.49%
|
-34.52
-379.63%
|
12.35
-50.52%
|
24.95
|
| Tax Provision |
|
15.38
+217.63%
|
4.84
-33.68%
|
7.30
+35.82%
|
5.38
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Tax Effect Of Unusual Items |
|
-10.52
-38.49%
|
-7.60
-379.63%
|
2.72
-50.52%
|
5.49
|
| Net Income Including Noncontrolling Interests |
|
-228.03
+39.69%
|
-378.08
+21.47%
|
-481.45
+17.45%
|
-583.19
|
| Net Income From Continuing Operation Net Minority Interest |
|
-228.03
+39.69%
|
-378.08
+21.47%
|
-481.45
+17.45%
|
-583.19
|
| Net Income From Continuing And Discontinued Operation |
|
-228.03
+39.69%
|
-378.08
+21.47%
|
-481.45
+17.45%
|
-583.19
|
| Net Income Continuous Operations |
|
-228.03
+39.69%
|
-378.08
+21.47%
|
-481.45
+17.45%
|
-583.19
|
| Normalized Income |
|
-190.74
+45.68%
|
-351.16
+28.49%
|
-491.08
+18.51%
|
-602.65
|
| Net Income Common Stockholders |
|
-228.03
+39.69%
|
-378.08
+21.47%
|
-481.45
+17.45%
|
-583.19
|
| Diluted EPS |
|
-3.76
+42.42%
|
-6.53
+23.63%
|
-8.55
+17.79%
|
-10.40
|
| Basic EPS |
|
-3.76
+42.42%
|
-6.53
+23.63%
|
-8.55
+17.79%
|
-10.40
|
| Basic Average Shares |
|
60.61
+4.69%
|
57.89
+0.00%
|
57.89
+3.25%
|
56.07
|
| Diluted Average Shares |
|
60.61
+4.69%
|
57.89
+0.00%
|
57.89
+3.25%
|
56.07
|
| Diluted NI Availto Com Stockholders |
|
-228.03
+39.69%
|
-378.08
+21.47%
|
-481.45
+17.45%
|
-583.19
|
| Depreciation Amortization Depletion Income Statement |
|
9.82
+39.10%
|
7.06
+25.59%
|
5.62
+4.58%
|
5.38
|
| Depreciation And Amortization In Income Statement |
|
9.82
+39.10%
|
7.06
+25.59%
|
5.62
+4.58%
|
5.38
|
| Depreciation Income Statement |
|
—
|
6.60
+17.32%
|
5.62
+4.58%
|
5.38
|
| Earnings From Equity Interest |
|
16.31
+181.30%
|
-20.06
-9.05%
|
-18.39
-3.94%
|
-17.70
|
| Total Other Finance Cost |
|
-20.47
-81.98%
|
-11.25
+23.24%
|
-14.65
-439.06%
|
4.32
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
1,302.57
+10.43%
|
1,179.49
+42.87%
|
825.59
-24.24%
|
1,089.74
|
| Current Assets |
|
1,108.98
+4.54%
|
1,060.86
+50.96%
|
702.72
-23.90%
|
923.47
|
| Cash Cash Equivalents And Short Term Investments |
|
616.04
+10.10%
|
559.54
+40.08%
|
399.44
-45.69%
|
735.46
|
| Cash And Cash Equivalents |
|
616.04
+10.10%
|
559.54
+42.68%
|
392.16
-11.83%
|
444.77
|
| Other Short Term Investments |
|
—
|
0.00
-100.00%
|
7.28
-97.50%
|
290.69
|
| Receivables |
|
157.70
-11.13%
|
177.44
+218.15%
|
55.77
+117.64%
|
25.63
|
| Accounts Receivable |
|
141.33
-15.00%
|
166.28
+363.51%
|
35.87
+201.21%
|
11.91
|
| Other Receivables |
|
14.58
+55.38%
|
9.38
-50.86%
|
19.10
+48.81%
|
12.83
|
| Taxes Receivable |
|
1.78
+0.34%
|
1.77
+121.32%
|
0.80
-9.17%
|
0.88
|
| Inventory |
|
301.53
+2.00%
|
295.61
+41.49%
|
208.93
+59.89%
|
130.67
|
| Raw Materials |
|
19.08
+8.45%
|
17.60
-5.22%
|
18.57
+93.07%
|
9.62
|
| Work In Process |
|
253.49
+7.55%
|
235.69
+37.81%
|
171.03
+51.51%
|
112.89
|
| Finished Goods |
|
28.96
-31.59%
|
42.33
+118.90%
|
19.34
+136.60%
|
8.17
|
| Prepaid Assets |
|
33.72
+19.26%
|
28.27
-26.72%
|
38.58
+21.63%
|
31.72
|
| Total Non Current Assets |
|
193.59
+63.18%
|
118.63
-3.44%
|
122.87
-26.10%
|
166.27
|
| Net PPE |
|
146.48
+48.39%
|
98.71
-10.77%
|
110.63
-14.30%
|
129.09
|
| Gross PPE |
|
222.90
+21.56%
|
183.36
+0.66%
|
182.15
+3.65%
|
175.74
|
| Accumulated Depreciation |
|
-76.42
+9.72%
|
-84.65
-18.36%
|
-71.52
-53.31%
|
-46.65
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
22.77
+3.79%
|
21.93
-20.06%
|
27.44
+9.99%
|
24.94
|
| Other Properties |
|
193.09
+36.82%
|
141.13
+4.28%
|
135.34
+3.57%
|
130.67
|
| Leases |
|
7.05
-65.28%
|
20.30
+4.76%
|
19.38
-3.75%
|
20.13
|
| Goodwill And Other Intangible Assets |
|
3.71
-7.89%
|
4.03
-8.85%
|
4.42
-8.47%
|
4.83
|
| Goodwill |
|
3.50
+0.00%
|
3.50
+0.00%
|
3.50
+0.00%
|
3.50
|
| Other Intangible Assets |
|
0.21
-59.66%
|
0.53
-42.32%
|
0.92
-30.68%
|
1.33
|
| Investments And Advances |
|
32.53
+139.60%
|
13.57
+138.74%
|
5.69
-81.31%
|
30.42
|
| Long Term Equity Investment |
|
32.53
+139.60%
|
13.57
+138.74%
|
5.69
-75.20%
|
22.93
|
| Non Current Accounts Receivable |
|
10.87
+369.14%
|
2.32
+8.93%
|
2.13
+10.78%
|
1.92
|
| Total Liabilities Net Minority Interest |
|
1,465.39
+14.02%
|
1,285.20
+32.32%
|
971.28
+17.53%
|
826.39
|
| Current Liabilities |
|
1,069.39
+17.79%
|
907.86
+23.27%
|
736.51
+2.75%
|
716.78
|
| Payables And Accrued Expenses |
|
97.08
-0.54%
|
97.62
+0.78%
|
96.86
-9.07%
|
106.52
|
| Payables |
|
97.08
-0.54%
|
97.62
+0.78%
|
96.86
-9.07%
|
106.52
|
| Accounts Payable |
|
90.66
-5.95%
|
96.39
+1.93%
|
94.57
-6.40%
|
101.03
|
| Total Tax Payable |
|
6.43
+425.94%
|
1.22
-46.85%
|
2.30
-58.12%
|
5.49
|
| Income Tax Payable |
|
6.43
+425.94%
|
1.22
-46.85%
|
2.30
-58.12%
|
5.49
|
| Current Debt And Capital Lease Obligation |
|
486.53
-1.02%
|
491.54
+16.68%
|
421.27
+2.01%
|
412.98
|
| Current Debt |
|
486.53
-1.02%
|
491.54
+16.68%
|
421.27
+2.01%
|
412.98
|
| Other Current Borrowings |
|
486.53
-1.02%
|
491.54
+16.68%
|
421.27
+2.01%
|
412.98
|
| Current Capital Lease Obligation |
|
—
|
—
|
14.17
+2.78%
|
13.79
|
| Current Deferred Liabilities |
|
4.94
+428.21%
|
0.94
-20.95%
|
1.18
|
0.00
|
| Current Deferred Revenue |
|
4.94
+428.21%
|
0.94
-20.95%
|
1.18
|
0.00
|
| Other Current Liabilities |
|
314.44
+43.82%
|
218.63
+18.51%
|
184.47
-2.88%
|
189.94
|
| Total Non Current Liabilities Net Minority Interest |
|
396.00
+4.95%
|
377.34
+60.72%
|
234.78
+114.19%
|
109.61
|
| Long Term Debt And Capital Lease Obligation |
|
385.25
+5.53%
|
365.08
+63.72%
|
223.00
+133.75%
|
95.40
|
| Long Term Debt |
|
385.25
+5.53%
|
365.08
+63.72%
|
223.00
+133.75%
|
95.40
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
84.62
-11.30%
|
95.40
|
| Non Current Deferred Liabilities |
|
10.75
-12.33%
|
12.26
+4.07%
|
11.78
-17.13%
|
14.21
|
| Non Current Deferred Revenue |
|
1.12
-77.54%
|
5.00
-15.95%
|
5.95
-58.14%
|
14.21
|
| Non Current Deferred Taxes Liabilities |
|
9.62
+32.58%
|
7.26
+24.49%
|
5.83
|
0.00
|
| Stockholders Equity |
|
-162.82
-54.03%
|
-105.71
+27.45%
|
-145.70
-155.32%
|
263.35
|
| Common Stock Equity |
|
-162.82
-54.03%
|
-105.71
+27.45%
|
-145.70
-155.32%
|
263.35
|
| Capital Stock |
|
8.32
+2.12%
|
8.15
+5.16%
|
7.75
+0.96%
|
7.67
|
| Common Stock |
|
8.32
+2.12%
|
8.15
+5.16%
|
7.75
+0.96%
|
7.67
|
| Share Issued |
|
61.98
+2.12%
|
60.69
+5.17%
|
57.71
-0.96%
|
58.27
|
| Ordinary Shares Number |
|
61.38
+2.57%
|
59.84
+5.70%
|
56.61
-0.94%
|
57.15
|
| Treasury Shares Number |
|
0.60
-29.41%
|
0.85
-22.61%
|
1.09
-1.81%
|
1.11
|
| Gains Losses Not Affecting Retained Earnings |
|
—
|
—
|
-153.45
-160.02%
|
255.67
|
| Total Equity Gross Minority Interest |
|
-162.82
-54.03%
|
-105.71
+27.45%
|
-145.70
-155.32%
|
263.35
|
| Total Capitalization |
|
222.43
-14.24%
|
259.37
+235.55%
|
77.30
-78.45%
|
358.75
|
| Working Capital |
|
39.59
-74.12%
|
153.00
+552.82%
|
-33.79
-116.35%
|
206.69
|
| Invested Capital |
|
708.97
-5.59%
|
750.91
+50.61%
|
498.57
-35.40%
|
771.73
|
| Total Debt |
|
871.79
+1.77%
|
856.62
+32.96%
|
644.26
+26.73%
|
508.38
|
| Net Debt |
|
255.75
-13.91%
|
297.07
+17.84%
|
252.10
+296.32%
|
63.61
|
| Capital Lease Obligations |
|
—
|
—
|
98.79
-9.52%
|
109.19
|
| Net Tangible Assets |
|
-166.53
-51.76%
|
-109.73
+26.90%
|
-150.12
-158.07%
|
258.52
|
| Tangible Book Value |
|
-166.53
-51.76%
|
-109.73
+26.90%
|
-150.12
-158.07%
|
258.52
|
| Available For Sale Securities |
|
—
|
—
|
—
|
7.49
|
| Current Provisions |
|
166.40
+67.82%
|
99.15
+203.03%
|
32.72
+345.82%
|
7.34
|
| Derivative Product Liabilities |
|
—
|
—
|
143.30
-9.28%
|
157.95
|
| Investmentin Financial Assets |
|
—
|
0.00
|
0.00
-100.00%
|
7.49
|
| Investmentsin Associatesat Cost |
|
32.53
+139.60%
|
13.57
+138.74%
|
5.69
-75.20%
|
22.93
|
| Other Equity Interest |
|
-171.14
-50.32%
|
-113.86
+25.80%
|
-153.45
-160.02%
|
255.67
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
53.90
+117.60%
|
-306.20
+34.48%
|
-467.36
+5.72%
|
-495.70
|
| Cash Flow From Continuing Operating Activities |
|
53.90
+117.60%
|
-306.20
+34.48%
|
-467.36
+5.72%
|
-495.70
|
| Net Income From Continuing Operations |
|
-228.03
+39.69%
|
-378.08
+21.47%
|
-481.45
+17.45%
|
-583.19
|
| Depreciation Amortization Depletion |
|
17.70
-0.10%
|
17.71
-6.33%
|
18.91
+5.31%
|
17.96
|
| Depreciation |
|
17.21
-0.24%
|
17.25
-6.41%
|
18.43
+5.22%
|
17.51
|
| Amortization Cash Flow |
|
0.49
+4.93%
|
0.47
-3.31%
|
0.48
+8.78%
|
0.44
|
| Depreciation And Amortization |
|
17.70
-0.10%
|
17.71
-6.33%
|
18.91
+5.31%
|
17.96
|
| Amortization Of Intangibles |
|
0.49
+4.93%
|
0.47
-3.31%
|
0.48
+8.78%
|
0.44
|
| Other Non Cash Items |
|
87.06
+83.86%
|
47.35
+2306.38%
|
-2.15
+49.40%
|
-4.24
|
| Stock Based Compensation |
|
116.17
+21.63%
|
95.51
+43.28%
|
66.66
+3.86%
|
64.18
|
| Provisionand Write Offof Assets |
|
—
|
—
|
—
|
6.14
|
| Asset Impairment Charge |
|
5.28
|
0.00
-100.00%
|
7.83
|
0.00
|
| Deferred Tax |
|
15.38
+217.63%
|
4.84
-33.68%
|
7.30
+35.82%
|
5.38
|
| Deferred Income Tax |
|
15.38
+217.63%
|
4.84
-33.68%
|
7.30
+35.82%
|
5.38
|
| Operating Gains Losses |
|
-16.31
-181.67%
|
19.97
+8.53%
|
18.40
+3.84%
|
17.72
|
| Gain Loss On Sale Of PPE |
|
0.00
+100.00%
|
-0.09
-1920.00%
|
0.01
-77.27%
|
0.02
|
| Change In Working Capital |
|
70.96
+166.22%
|
-107.16
-7.39%
|
-99.79
-700.08%
|
-12.47
|
| Change In Receivables |
|
15.59
+113.14%
|
-118.61
-261.90%
|
-32.77
-184.22%
|
-11.53
|
| Change In Inventory |
|
-5.92
+93.17%
|
-86.68
-10.76%
|
-78.26
-41.60%
|
-55.27
|
| Change In Prepaid Assets |
|
-6.05
-158.23%
|
10.39
+191.05%
|
-11.41
-78.08%
|
-6.41
|
| Change In Payables And Accrued Expense |
|
-10.37
-138.47%
|
26.96
+659.36%
|
3.55
-92.27%
|
45.94
|
| Change In Other Working Capital |
|
77.72
+27.88%
|
60.77
+218.06%
|
19.11
+29.16%
|
14.79
|
| Investing Cash Flow |
|
-8.48
-223.40%
|
6.88
-97.60%
|
286.47
+364.06%
|
61.73
|
| Cash Flow From Continuing Investing Activities |
|
-8.48
-223.40%
|
6.88
-97.60%
|
286.47
+364.06%
|
61.73
|
| Net PPE Purchase And Sale |
|
-8.48
-1678.83%
|
-0.48
+80.05%
|
-2.39
+51.74%
|
-4.95
|
| Purchase Of PPE |
|
-8.48
-494.60%
|
-1.43
+41.56%
|
-2.44
+83.15%
|
-14.49
|
| Sale Of PPE |
|
0.00
-100.00%
|
0.95
+1762.75%
|
0.05
-99.47%
|
9.54
|
| Capital Expenditure |
|
-8.48
-494.60%
|
-1.43
+41.56%
|
-2.44
+83.15%
|
-14.49
|
| Capital Expenditure Reported |
|
—
|
—
|
—
|
—
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
7.35
-97.45%
|
288.87
+333.17%
|
66.69
|
| Purchase Of Investment |
|
—
|
0.00
|
0.00
+100.00%
|
-213.84
|
| Sale Of Investment |
|
0.00
-100.00%
|
7.35
-97.45%
|
288.87
+2.97%
|
280.53
|
| Net Business Purchase And Sale |
|
—
|
—
|
0.00
|
0.00
|
| Purchase Of Business |
|
—
|
—
|
0.00
|
0.00
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
0.00
|
0.00
|
| Purchase Of Intangibles |
|
—
|
—
|
0.00
|
0.00
|
| Financing Cash Flow |
|
36.33
-91.82%
|
443.93
+230.57%
|
134.29
-66.15%
|
396.77
|
| Cash Flow From Continuing Financing Activities |
|
36.33
-91.82%
|
443.93
+230.57%
|
134.29
-66.15%
|
396.77
|
| Net Issuance Payments Of Debt |
|
-21.96
-117.88%
|
122.79
-2.40%
|
125.82
-74.68%
|
496.93
|
| Issuance Of Debt |
|
0.00
-100.00%
|
134.16
-1.54%
|
136.26
-72.93%
|
503.28
|
| Repayment Of Debt |
|
-21.96
-93.21%
|
-11.37
-8.88%
|
-10.44
-64.22%
|
-6.36
|
| Long Term Debt Issuance |
|
0.00
-100.00%
|
134.16
-1.54%
|
136.26
-72.93%
|
503.28
|
| Long Term Debt Payments |
|
-21.96
-93.21%
|
-11.37
-8.88%
|
-10.44
-64.22%
|
-6.36
|
| Net Long Term Debt Issuance |
|
-21.96
-117.88%
|
122.79
-2.40%
|
125.82
-74.68%
|
496.93
|
| Net Common Stock Issuance |
|
-17.40
-105.61%
|
309.91
|
0.00
+100.00%
|
-105.31
|
| Common Stock Payments |
|
-17.40
|
0.00
|
0.00
+100.00%
|
-105.31
|
| Repurchase Of Capital Stock |
|
-17.40
|
0.00
|
0.00
+100.00%
|
-105.31
|
| Proceeds From Stock Option Exercised |
|
87.08
+185.37%
|
30.51
+196.66%
|
10.29
+99.61%
|
5.15
|
| Net Other Financing Charges |
|
-11.40
+40.93%
|
-19.29
-964.62%
|
-1.81
|
—
|
| Changes In Cash |
|
81.74
-43.47%
|
144.61
+410.35%
|
-46.59
-25.28%
|
-37.19
|
| Effect Of Exchange Rate Changes |
|
-25.24
-210.85%
|
22.77
+479.01%
|
-6.01
-116.83%
|
35.69
|
| Beginning Cash Position |
|
559.54
+42.68%
|
392.16
-11.83%
|
444.77
-0.34%
|
446.27
|
| End Cash Position |
|
616.04
+10.10%
|
559.54
+42.68%
|
392.16
-11.83%
|
444.77
|
| Free Cash Flow |
|
45.41
+114.76%
|
-307.62
+34.52%
|
-469.80
+7.92%
|
-510.19
|
| Common Stock Issuance |
|
0.00
-100.00%
|
309.91
|
0.00
|
0.00
|
| Earnings Losses From Equity Investments |
|
-16.31
-181.30%
|
20.06
+9.05%
|
18.39
+3.94%
|
17.70
|
| Interest Paid CFO |
|
-22.93
-50.84%
|
-15.21
+2.98%
|
-15.67
-68.62%
|
-9.29
|
| Interest Received CFO |
|
15.30
+6.46%
|
14.37
-15.69%
|
17.05
+106.12%
|
8.27
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
309.91
|
0.00
|
0.00
|
| Taxes Refund Paid |
|
-6.68
-21.17%
|
-5.51
-23.42%
|
-4.47
-148766.67%
|
-0.00
|
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|